Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

CONCLUSION: Rilotumumab with BEV did not significantly improve objective response compared with BEV alone, and toxicity may preclude the use of rilotumumab in combination BEV regimens.
PMID: 29666296 [PubMed - as supplied by publisher]

Source: The Oncologist - April 17, 2018 Category: Cancer & Oncology Authors: Affronti ML, Jackman JG, McSherry F, Herndon JE, Massey EC, Lipp E, Desjardins A, Friedman HS, Vlahovic G, Vredenburgh J, Peters KB Tags: Oncologist Source Type: research